Related Experiment Videos
Oral anticoagulation therapy in children
1Servicio de Hematolgía y Oncología, Hospital de Pediatría "Prof. Dr. JP Garrahan", Buenos Aires, Argentina. mbonduel@garrahan.com.ar
Insights
Oral anticoagulant therapy in children, primarily using warfarin, presents challenges. Infants require dose adjustments and frequent monitoring for effective treatment of thromboembolic complications.
Area of Science:
- Pediatric Thrombosis and Anticoagulation
- Pharmacology and Therapeutics
Background:
- Oral anticoagulant therapy in children is primarily based on adult data.
- Coumarin derivatives, including warfarin, are the mainstays of treatment for pediatric thromboembolic complications.
Purpose of the Study:
- To review current practices, challenges, and guidelines for oral anticoagulant therapy in children.
- To discuss indications, side effects, and reversal of anticoagulation in pediatric patients.
Main Methods:
- Analysis of prospective studies from Canada and Argentina on warfarin and acenocoumarol administration.
- Review of existing literature on pediatric anticoagulant therapy and monitoring.
Main Results:
- Pediatric oral anticoagulant therapy, especially in infants under 12 months, is complex.
- Infants require higher doses, careful loading dose adjustments, frequent monitoring, and more frequent dose adjustments to maintain therapeutic International Normalized Ratio (INR).
- Achieving and maintaining the target INR range is more challenging in younger children.
Conclusions:
- Current guidelines for oral anticoagulants in children highlight significant difficulties in administration and monitoring.
- Specialized approaches are needed for effective and safe anticoagulation in pediatric patients, particularly infants.
- Further research is warranted to optimize anticoagulant regimens for children.
Abstract:
Treatment of thromboembolic complications in children has been the subject of considerable research in the last decade. Recommendations for oral anticoagulant therapy in children have been extrapolated from adult clinical trials. Coumarin derivatives are the preeminent oral antithrombotic agents used in children. Warfarin, acenocoumarol and phenprocoumon are the vitamin K antagonists used in children with thrombotic complications in different countries according to their experience and familiarity within a country or region. Prospective studies from Canada and Argentina propose guidelines for administering and monitoring warfarin and acenocoumarol therapy in children. These studies highlight the difficulty of their use in pediatric patients. Infants younger than 12 months of age require increased doses to achieve and maintain the therapeutic target INR, adjustments of loading dose to achieve the target INR faster with no overshooting, more frequent INR testing and dose adjustments, and fewer INR in the target range. The current indications for oral anticoagulants in children with thrombotic complications, the side effects of these agents and the reversal of the anticoagulant effect are discussed.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Drug Dosing: Infants and Children
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Venous Thrombosis IV: Nursing Management